Drugs /

tamoxifen

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
tamoxifen
Trade Name(s):
Tamoxasta, Jenoxifen, Emblon, Soltamox, Nourytam, Tamizam, Tamofen, Nolvadex, Ebefen, Tamax, Fentamox, Apo-Tamox, Lesporene, Tamifen, Novo-Tamoxifen, Kessar, Nolvadex-D, Oncotam, Gen-Tamoxifen, Nolgen, Clonoxifen, Noltam, Ledertam, Tamaxin, Dignotamoxi, Pms-Tamoxifen, Oestrifen, Estroxyn, Zemide, Novaldex, Genox, and Novofen
NCI Definition [1]:
An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for tamoxifen

Tamoxifen has been investigated in 43 clinical trials, of which 31 are open and 12 are closed. Of the trials investigating tamoxifen, 2 are early phase 1 (2 open), 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 28 are phase 2 (19 open), 1 is phase 2/phase 3 (1 open), 6 are phase 3 (6 open), and 2 are no phase specified (0 open).

ER Positive, ER Expression, and PR Positive are the most frequent biomarker inclusion criteria for tamoxifen clinical trials.

Breast carcinoma, ductal carcinoma in situ, and bladder papillary urothelial carcinoma are the most common diseases being investigated in tamoxifen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tamoxifen
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tamoxifen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tamoxifen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Nolvadex, Novaldex, Apo-Tamox, Clonoxifen, Dignotamoxi, Ebefen, Emblon, Estroxyn, Fentamox, Genox, Gen-Tamoxifen, Jenoxifen, Kessar, Ledertam, Lesporene, Nolgen, Noltam, Nolvadex-D, Nourytam, Novofen, Novo-Tamoxifen, Oestrifen, Oncotam, PMS-Tamoxifen, Soltamox, Tamax, Tamaxin, Tamifen, Tamizam, Tamofen, Tamoxasta, Zemide, ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethyl-, (z)-, 1-p-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, tamoxifen (product), 1-para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, tamoxifene, tmx, tamoxifen [chemical/ingredient], tamoxifen, tamoxifène, tamoxifeno, tamoxifen (substance), (z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-n,n-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (1:1), tamoxifenum, (z)-2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylethanamine, tam, (z)-2-(para-(1,2-diphenyl-1-butenyl)phenoxy)-n,n-dimethylamine, 1-p-beta-dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene, tamoxifen
Drug Categories [2]:
Selective estrogen receptor modulators (SERMs), Serine/threonine kinase inhibitors
Drug Target(s) [2]:
ESR1, ESR2
NCIT ID [1]:
C62078
SNOMED ID [1]:
C-781E0

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.